title: Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15.
abstract: Advanced Glycation End-Products (AGEs), a group of compounds resulting from the non-enzymatic reaction of reducing sugars with the free amino group of proteins, are implicated in diabetic complications. We previously demonstrated that exposure of the pancreatic islet cell line HIT-T 15 to high concentrations of AGEs significantly decreases cell proliferation and insulin secretion, and affects transcription factors regulating insulin gene transcription. The glucagon-like peptide-1 (GLP-1) is an incretin hormone that increases proinsulin biosynthesis, stimulates insulin secretion, and improves pancreatic beta-cell viability. The aim of this work was to investigate the effects of GLP-1 on the function and viability of HIT-T 15 cells cultured with AGEs. HIT-T 15 cells were cultured for 5days in presence of AGEs alone, or supplemented with 10nmol/l GLP-1. Cell viability, insulin secretion, redox balance, and expression of the AGEs receptor (RAGE) were then determined. The results showed that GLP-1 protected beta cell against AGEs-induced cell death preventing both apoptosis and necrosis. Moreover, addition of GLP-1 to the AGEs culture medium restored the redox balance, improved the responsiveness to glucose, and attenuated AGEs-induced RAGE expression. These findings provide evidence that GLP-1 protects beta cells from the dangerous effects of AGEs.
authors.affiliation: University of Genova, Department of Internal Medicine and Medical Specialties, Viale Benedetto XV, 16132 Genova, Italy. alep100@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Puddu
authors.forename: D
authors.initials: D
authors.lastname: Storace
authors.forename: A
authors.initials: A
authors.lastname: Durante
authors.forename: P
authors.initials: P
authors.lastname: Odetti
authors.forename: G L
authors.initials: GL
authors.lastname: Viviani
mesh_terms: D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D019610:Cytoprotection; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology*; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors* / Q000633:toxicity; D006801:Humans; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000502:physiology
chemical_list: D017127:Glycation End Products, Advanced; D052216:Glucagon-Like Peptide 1